The KEYNOTE‐598 trial showed that adding ipilimumab to the pembrolizumab regimen did not improve efficacy and, compared with using pembrolizumab alone as a first‐line treatment for metastatic NSCLC with PD‐L1 tumour proportion score ≥50% and no targetable EGFR or ALK abnormalities, it resulted in greater toxicity.247. This evidence concerns the gene EGFR and neoplasm.